Cargando…

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

IMPORTANCE: Patients with refractory hypercholesterolemia who do not achieve their guideline-defined low-density lipoprotein cholesterol (LDL-C) thresholds despite treatment with maximally tolerated combinations of lipid-lowering therapies (LLTs) have an increased risk of atherosclerotic cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenson, Robert S., Burgess, Lesley J., Ebenbichler, Christoph F., Baum, Seth J., Stroes, Erik S. G., Ali, Shazia, Khilla, Nagwa, McGinniss, Jennifer, Gaudet, Daniel, Pordy, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500429/ https://www.ncbi.nlm.nih.gov/pubmed/37703006 http://dx.doi.org/10.1001/jamacardio.2023.2921

Ejemplares similares

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
por: Rosenson, Robert S., et al.
Publicado: (2023)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
por: Krzemińska, Julia, et al.
Publicado: (2022)

Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia
por: Sosnowska, Bożena, et al.
Publicado: (2022)

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
por: Banerjee, Poulabi, et al.
Publicado: (2019)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

OR24-02 Case Series Of Canadian Patients With Homozygous Familial Hypercholesterolemia Treated With ANGPTL3 Inhibitor Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience
por: Stefanutti, Claudia, et al.
Publicado: (2022)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
por: Surma, Stanisław, et al.
Publicado: (2021)

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report
por: Reeskamp, Laurens F., et al.
Publicado: (2021)

Cómo se vende un presidente /
por: McGinniss, Joe
Publicado: (1974)

Cómo se vende un presidente /
por: McGinniss, Joe
Publicado: (1970)

Existing and emerging therapies for the treatment of familial hypercholesterolemia
por: Rosenson, Robert S.
Publicado: (2021)

Shifting the Overton Window on Nontuberculous Mycobacterial Disease Infection Susceptibility by Race
por: McGinniss, John E.
Publicado: (2023)

Evidence-Based, Mechanistic Approach to the Management of Homozygous Familial Hypercholesterolemia
por: Rosenson, Robert S.
Publicado: (2022)

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
por: Laufs, Ulrich, et al.
Publicado: (2019)

The Upper Airway Microbiome and Lung Injury in COVID-19
por: McGinniss, John E., et al.
Publicado: (2021)

Tracer Exchange vs. Net Uptake of Glucose through Human Red Cell Surface : New evidence for carrier-mediated diffusion
por: LeFevre, P. G., et al.
Publicado: (1960)

Musculoskeletal Imaging for Low Back Pain in Direct Access Physical Therapy Compared to Primary Care: An Observational Study
por: Crowell, Michael S, et al.
Publicado: (2022)

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice
por: Pouwer, Marianne G., et al.
Publicado: (2020)

Multiple Property Tolerance Analysis for the Evaluation of Missense Mutations
por: Lee, Tai-Sung, et al.
Publicado: (2007)

Distinguishing Lysosomal Acid Lipase Deficiency From Familial Hypercholesterolemia
por: Sheth, Sohum, et al.
Publicado: (2023)

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab
por: Khaksar Toroghi, Masood, et al.
Publicado: (2021)

Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report
por: Fachin, Alice, et al.
Publicado: (2023)

The Effect of Blood Flow Restriction Therapy on Shoulder Function Following Shoulder Stabilization Surgery: A Case Series
por: McGinniss, John H., et al.
Publicado: (2022)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy
por: Li, Zhi-Fan, et al.
Publicado: (2022)

Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia
por: Khoury, Etienne, et al.
Publicado: (2020)

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
por: Bays, Harold E., et al.
Publicado: (2017)

Low-Cost High-Throughput Genotyping for Diagnosing Familial Hypercholesterolemia
por: Ibrahim, Shirin, et al.
Publicado: (2023)

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2022)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
por: Colhoun, Helen M, et al.
Publicado: (2014)

Technical Standards and Guidelines for Fragile X: The First of a Series of Disease-Specific Supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics
por: Maddalena, Anne, et al.
Publicado: (2001)

Severe Dyslipidemia Mimicking Familial Hypercholesterolemia Induced by High-Fat, Low-Carbohydrate Diets: A Critical Review
por: Houttu, Veera, et al.
Publicado: (2023)

4167 Peri-transplant Lung Microbiome Reveal Oral Bacteria, Pepsin And Inflammatory Markers Co-associate With Primary Graft Dysfunction, Implicating Aspiration As A Potential Contributor
por: McGinniss, John Evan, et al.
Publicado: (2020)

THU402 New Heterotopic Ossification Lesions In Patients With Fibrodysplasia Ossificans Progressiva Measured By PET/CT vs CT Only
por: Trotter, Dinko Gonzalez, et al.
Publicado: (2023)

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease
por: Weintraub, Spencer F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_anbf3a76tch7de43qclb6s0dhf